Literature DB >> 27404708

Cardiovascular risk and treatment for adults with intellectual or developmental disabilities.

Steven R Erickson1, Patrick Spoutz2, Michael Dorsch3, Barry Bleske4.   

Abstract

BACKGROUND: People with intellectual/developmental disabilities (IDDs) face the development of cardiovascular disease (CVD) similar to the general population. The purpose of this study was to describe and compare the presence of CVD risk factors, the atherosclerotic cardiovascular (ASCVD) risk score, and medication prescribing patterns for medications to treat related risk factors for patients with IDD and those without.
METHODS: This was a retrospective study of patients age 18years and older of a health system's primary care medicine practices. The IDD group had documentation of a diagnosis related to IDD. The comparison group was a random sample of patients from the same practices who had no indication of IDD. Patient characteristics included demographics, smoking status, cholesterol, and blood pressure. The presence of a diagnosis of hypertension, hyperlipidemia, diabetes, coronary artery disease, history of stroke or myocardial infarction, and related medication therapy were documented. The dependent variable was the estimated 10-year primary risk of ASCVD.
RESULTS: The IDD group included 78 patients while the GenMed group included 187. There were no significant differences in the prevalence of risk-related diagnoses or in blood pressure and cholesterol between the two groups. The estimated 10-year ASCVD risk was significantly higher in the GenMed group compared to the IDD group (p=0.02). Prescribing was similar between the groups. The regression analysis found that group assignment was not significantly associated with ASCVD risk, while age, gender, and race were.
CONCLUSIONS: CV risk and related treatment among patients with IDD was similar to that of the general population.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Developmental disabilities; General medicine

Mesh:

Substances:

Year:  2016        PMID: 27404708     DOI: 10.1016/j.ijcard.2016.07.044

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Changes in Energy Intake and Diet Quality during an 18-Month Weight-Management Randomized Controlled Trial in Adults with Intellectual and Developmental Disabilities.

Authors:  Lauren T Ptomey; Felicia L Steger; Jaehoon Lee; Debra K Sullivan; Jeannine R Goetz; Jeffery J Honas; Richard A Washburn; Cheryl A Gibson; Joseph E Donnelly
Journal:  J Acad Nutr Diet       Date:  2018-01-06       Impact factor: 4.910

2.  Testing a Wellness Indicators Measure for People with Intellectual and Developmental Disabilitiesa.

Authors:  Matthew Bogenschutz; Michael Broda; Sarah Lineberry; Parthenia Dinora; Seb Prohn
Journal:  Dev Disabil Netw J       Date:  2021

3.  Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database.

Authors:  Steven R Erickson; Tanima Basu; Michael P Dorsch; Neil Kamdar
Journal:  Ann Pharmacother       Date:  2020-04-27       Impact factor: 3.154

Review 4.  Exploring chronic disease prevalence in people with intellectual disabilities in primary care settings: A scoping review.

Authors:  Milou van den Bemd; Maarten Cuypers; Erik W M A Bischoff; Marloes Heutmekers; Bianca Schalk; Geraline L Leusink
Journal:  J Appl Res Intellect Disabil       Date:  2021-11-08

5.  Chronic Health Conditions in Aging Individuals with Intellectual Disabilities.

Authors:  Laura García-Domínguez; Patricia Navas; Miguel Ángel Verdugo; Víctor B Arias
Journal:  Int J Environ Res Public Health       Date:  2020-04-30       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.